ResApp Health Limited (RAP) 2016年年度报告「ASX」.pdf

1、 ResApp Health Limited(formerly Narhex Life Sciences Limited)ABN 51 094 468 318 CONSOLIDATED ANNUAL REPORT for the year ended 30 June 2016 ResApp Health Limited Consolidated Annual Report ABN 51 094 468 318 CONTENTS TO THE CONSOLIDATED FINANCIAL REPORT Corporate information.1 Directors report.2 Corp

2、orate governance statement.9 Auditors independence declaration.21 Consolidated statement of profit or loss and other comprehensive income for the financial year ended 30 June 2016.22 Consolidated statement of financial position as at 30 June 2016.23 Consolidated statement of changes in equity for th

3、e financial year ended 30 June 2016.24 Consolidated statement of cash flows for the financial year ended 30 June 2016.25 Notes to the consolidated financial statements.26 Directors declaration.45 Independent auditors report.46 ASX additional information.48 ResApp Health Limited Annual Report ABN 51

4、094 468 318 1 Corporate information This annual report is for ResApp Health Limited(formerly Narhex Life Sciences Limited)and its controlled entity(“the Group”).Unless otherwise stated,all amounts are presented in Australian Dollars.A description of the Groups operations and of its principal activit

5、ies is included in the review of operations and activities in the directors report on pages 5 to 8.The directors report is not part of the financial statements.Directors Dr Roger Aston(appointed 2 July 2015)Dr Tony Keating(appointed 2 July 2015)Mr Brian Leedman(appointed 19 February 2016)Mr Chris Nt

6、oumenopoulos(appointed 21 January 2015)Mr Adam Sierakowski(resigned on 22 March 2016)Dr Robert Ramsay(resigned on 2 July 2015)Company Secretary Ms Nicki Farley Registered and Principal Office Auditors Level 24 Greenwich&Co Audit Pty Ltd 44 St Georges Tce,Level 2,35 Outram St PERTH WA 6000 PERTH WA 6